cannabidiol/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Increases seizure frequency 50% responder rate
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1“In the overall DS population, CBD resulted in a greater reduction in convulsive seizures (0.71 [0.60‐0.83], p < 0.0001) and higher ≥50% responder rates (2.34 [1.51‐3.63], p = 0.0001) compared with placebo.”
Quoted verbatim from Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials.. - Study
- meta-analysis
- Duration
- 3 months
- Dose
- 10 or 20 mg/kg/day oral solution for 14 weeks
- Population
- Patients aged 2 to 18 years with Dravet syndrome in two pooled phase 3 trials (GWPCARE1B and GWPCARE2), all CBD doses (10 and 20 mg/kg/day) versus placebo, overall population; concomitant antiepileptic drugs in both arms
Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials.2021PMID:32969022Industry fundedPermalink
Keep reading
- Everything the graph holds on cannabidiol
- Every compound studied against Seizure frequency 50% responder rate
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M45HMRN9F31JVX9C0S76GYS7